A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

Dementia With Lewy Bodies (DLB) Clinical Trial

Official title:
A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00598650
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	February 2008
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04001517` - Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies	Phase 2
Recruiting	`NCT03030586` - ADDIA Proof-of-Performance Clinical Study
Completed	`NCT00776347` - Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)	N/A
Withdrawn	`NCT04055532` - Biomarkers in Neurodegenerative Diseases
Completed	`NCT00543855` - A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)	Phase 2
Completed	`NCT01278407` - A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	Phase 3